文献速递精神分裂症与精神病性障碍

抗精神病药治疗急性精神分裂症的剂量-效应荟萃分析

Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
PubMed 文献 · Am J Psychiatry · 2019-12-16

研究确定了各药物的95%有效剂量及与1 mg口服利培酮等效的剂量,发现高于95%有效剂量的剂量平均不会提供更多疗效,部分药物剂量-效应曲线未达平台期。

要点

  • 确定了20种第二代抗精神病药及氟哌啶醇的95%有效剂量和利培酮等效剂量。
  • 高于95%有效剂量的剂量平均不增加疗效,部分药物可测试更高剂量。
  • 提供了在线电子表格用于临床估算剂量等效性。

核心结论

  • 在慢性精神分裂症急性加重患者中,高于所确定95%有效剂量的剂量平均不会提供更多疗效。
  • 部分药物因剂量-效应曲线未达平台期,可在未来试验中测试高于当前许可的剂量。

研究设计与样本

  • 随机效应剂量-效应荟萃分析和样条模型,检索多个电子数据库至2018年11月。
  • 结局指标为PANSS或BPRS总分较基线的减分。

主要发现

  • 氨磺必利(针对阳性症状)95%有效剂量为537 mg/天,与1 mg口服利培酮等效剂量为85.8 mg。
  • 阿立哌唑95%有效剂量为11.5 mg/天,等效剂量为1.8 mg;阿立哌唑长效针剂(lauroxil)95%有效剂量为463 mg每4周,等效剂量为264 mg。
  • 氟哌啶醇95%有效剂量为6.3 mg/天,等效剂量为1.01 mg;奥氮平95%有效剂量为15.2 mg/天,等效剂量为2.4 mg。
  • 喹硫平95%有效剂量为482 mg/天,等效剂量为77 mg;利培酮95%有效剂量为6.3 mg/天,等效剂量为1 mg。
  • 齐拉西酮95%有效剂量为186 mg/天,等效剂量为30 mg。

关键数值与推荐

  • 氨磺必利95%有效剂量537 mg/天,等效剂量85.8 mg。
  • 阿立哌唑95%有效剂量11.5 mg/天,等效剂量1.8 mg。
  • 氟哌啶醇95%有效剂量6.3 mg/天,等效剂量1.01 mg。
  • 奥氮平95%有效剂量15.2 mg/天,等效剂量2.4 mg。
  • 利培酮95%有效剂量6.3 mg/天,等效剂量1 mg。

临床怎么用

  • 临床医生可参考95%有效剂量和等效剂量信息进行个体化剂量决策。
  • 对于剂量-效应曲线未达平台期的药物,可考虑在进一步试验中测试更高剂量。
  • 作者提供了在线电子表格,可用于临床估算剂量等效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The dose-response relationships of antipsychotic drugs for schizophrenia are not well defined, but such information would be important for decision making by clinicians. The authors sought to fill this gap by conducting dose-response meta-analyses. METHODS: A search of multiple electronic databases (through November 2018) was conducted for all placebo-controlled dose-finding studies for 20 second-generation antipsychotic drugs and haloperidol (oral and long-acting injectable, LAI) in people with acute schizophrenia symptoms. Dose-response curves were constructed with random-effects dose-response meta-analyses and a spline model. The outcome measure was total score reduction from baseline on the Positive and Negative Syndrome Scale or the Brief Psychiatric Rating Scale. The authors identified 95% effective doses, explored whether higher or lower doses than the currently licensed ones might be more appropriate, and derived dose equivalencies from the 95% effective doses. RESULTS: Sixty-eight studies met the inclusion criteria. The 95% effective doses and the doses equivalent to 1 mg of oral risperidone, respectively, were as follows: amisulpride for patients with positive symptoms, 537 mg/day and 85.8 mg; aripiprazole, 11.5 mg/day and 1.8 mg; aripiprazole LAI (lauroxil), 463 mg every 4 weeks and 264 mg; asenapine, 15.0 mg/day and 2.4 mg; brexpiprazole, 3.36 mg/day and 0.54 mg; haloperidol, 6.3 mg/day and 1.01 mg; iloperidone, 20.13 mg/day and 3.2 mg; lurasidone, 147 mg/day and 23.5 mg; olanzapine, 15.2 mg/day and 2.4 mg; olanzapine LAI, 277 mg every 2 weeks and 3.2 mg; paliperidone, 13.4 mg/day and 2.1 mg; paliperidone LAI, 120 mg every 4 weeks and 1.53 mg; quetiapine, 482 mg/day and 77 mg; risperidone, 6.3 mg/day and 1 mg; risperidone LAI, 36.6 mg every 2 weeks and 0.42 mg; sertindole, 22.5 mg/day and 3.6 mg; and ziprasidone, 186 mg/day and 30 mg. For amisulpride and olanzapine, specific data for patients with predominant negative symptoms were available. The authors have made available on their web site a spreadsheet with this method and other updated methods that can be used to estimate dose equivalencies in practice. CONCLUSIONS: In chronic schizophrenia patients with acute exacerbations, doses higher than the identified 95% effective doses may on average not provide more efficacy. For some drugs, higher than currently licensed doses might be tested in further trials, because their dose-response curves did not plateau.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Leucht S, Crippa A, Siafis S, et al. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. Am J Psychiatry. 2019. PMID: 31838873. doi:10.1176/appi.ajp.2019.19010034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。